{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VIGAMOX&page=5", "query": { "intervention": "VIGAMOX", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 309, "total_pages": 31, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VIGAMOX&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VIGAMOX&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T06:00:35.622Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06215521", "title": "A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Pirtobrutinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 31, "start_date": "2020-12-15", "completion_date": "2021-03-31", "has_results": true, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-11-07T06:00:35.622Z", "location_count": 2, "location_summary": "Dallas, Texas • Madison, Wisconsin", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06215521" }, { "nct_id": "NCT02062203", "title": "Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "AKB-6548 (therapeutic dose)", "type": "DRUG" }, { "name": "AKB-6548 (supratherapeutic dose)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akebia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 50, "start_date": "2014-01", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-11-07T06:00:35.622Z", "location_count": 1, "location_summary": "Evansville, Indiana", "locations": [ { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02062203" }, { "nct_id": "NCT05893862", "title": "A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Elpipodect", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 107, "start_date": "2023-06-26", "completion_date": "2024-02-22", "has_results": true, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-11-07T06:00:35.622Z", "location_count": 4, "location_summary": "Glendale, California • Orange, California • Hallandale, Florida + 1 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Hallandale", "state": "Florida" }, { "city": "Marlton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05893862" }, { "nct_id": "NCT00042289", "title": "Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "atazanavir/cobicistat", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #3", "type": "DRUG" }, { "name": "elvitegravir/cobicistat", "type": "DRUG" }, { "name": "dolutegravir", "type": "DRUG" }, { "name": "tenofovir alafenamide fumarate (TAF)", "type": "DRUG" }, { "name": "TAF w/cobicistat", "type": "DRUG" }, { "name": "TAF w/cobicistat or ritonavir", "type": "DRUG" }, { "name": "efavirenz", "type": "DRUG" }, { "name": "darunavir/cobicistat", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "atazanavir/ritonavir/tenofovir dosage #1", "type": "DRUG" }, { "name": "rifampicin", "type": "DRUG" }, { "name": "ethambutol", "type": "DRUG" }, { "name": "isoniazid", "type": "DRUG" }, { "name": "pyrazinamide", "type": "DRUG" }, { "name": "kanamycin", "type": "DRUG" }, { "name": "amikacin", "type": "DRUG" }, { "name": "capreomycin", "type": "DRUG" }, { "name": "moxifloxacin", "type": "DRUG" }, { "name": "levoflaxacin", "type": "DRUG" }, { "name": "ofloxacin", "type": "DRUG" }, { "name": "ethionamide/prothionamide", "type": "DRUG" }, { "name": "terizidone/cycloserine", "type": "DRUG" }, { "name": "para-aminosalicylic acid (PAS)", "type": "DRUG" }, { "name": "high dose INH", "type": "DRUG" }, { "name": "bedaquiline", "type": "DRUG" }, { "name": "clofazamine", "type": "DRUG" }, { "name": "delamanid", "type": "DRUG" }, { "name": "linezolid", "type": "DRUG" }, { "name": "pretomanid", "type": "DRUG" }, { "name": "ethinyl estradiol", "type": "DRUG" }, { "name": "etonogestrel implant", "type": "DRUG" }, { "name": "nevirapine", "type": "DRUG" }, { "name": "amprenavir", "type": "DRUG" }, { "name": "abacavir", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "indinavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "fosamprenavir/ritonavir", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #3", "type": "DRUG" }, { "name": "atazanavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "didanosine delayed release (Videx® EC)", "type": "DRUG" }, { "name": "emtricitabine", "type": "DRUG" }, { "name": "tenofovir", "type": "DRUG" }, { "name": "nelfinavir dosage #1", "type": "DRUG" }, { "name": "tipranavir/ritonavir", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #4", "type": "DRUG" }, { "name": "raltegravir", "type": "DRUG" }, { "name": "etravirine", "type": "DRUG" }, { "name": "maraviroc", "type": "DRUG" }, { "name": "atazanavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "tenofovir/atazanavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "nelfinavir dosage #2", "type": "DRUG" }, { "name": "indinavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "rilpivirine", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1578, "start_date": "2003-06-09", "completion_date": "2020-09-30", "has_results": true, "last_update_posted_date": "2025-12-02", "last_synced_at": "2026-11-07T06:00:35.622Z", "location_count": 39, "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00042289" }, { "nct_id": "NCT01243580", "title": "AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ortho-Cyclen", "type": "DRUG" }, { "name": "AG200-15", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agile Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 36, "start_date": "2009-08", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2018-01-23", "last_synced_at": "2026-11-07T06:00:35.622Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01243580" }, { "nct_id": "NCT02785770", "title": "A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PF-04447943", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 44, "start_date": "2016-06-29", "completion_date": "2016-10-20", "has_results": true, "last_update_posted_date": "2018-12-28", "last_synced_at": "2026-11-07T06:00:35.622Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02785770" }, { "nct_id": "NCT01090661", "title": "A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "mipomersen sodium", "type": "DRUG" }, { "name": "moxifloxacin hydrochloride (Avelox®)", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kastle Therapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 60, "start_date": "2010-03", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2016-08-03", "last_synced_at": "2026-11-07T06:00:35.622Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01090661" }, { "nct_id": "NCT00850746", "title": "A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Functional Dyspepsia" ], "interventions": [ { "name": "YM443", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 80, "start_date": "2009-02", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2014-03-24", "last_synced_at": "2026-11-07T06:00:35.622Z", "location_count": 1, "location_summary": "Tacoma, Washington", "locations": [ { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00850746" }, { "nct_id": "NCT01296542", "title": "A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cataracts" ], "interventions": [ { "name": "Moxifloxacin Ophthalmic", "type": "DRUG" }, { "name": "Besifloxacin Ophthalmic", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bucci Laser Vision Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2011-05", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-11-07T06:00:35.622Z", "location_count": 1, "location_summary": "Wilkes-Barre, Pennsylvania", "locations": [ { "city": "Wilkes-Barre", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01296542" }, { "nct_id": "NCT01263808", "title": "Cardiac Safety of Indacaterol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers", "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Indacaterol 150 µg", "type": "DRUG" }, { "name": "Indacaterol 300 µg", "type": "DRUG" }, { "name": "Indacaterol 600 µg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Placebo/moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 404, "start_date": "2008-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-12-21", "last_synced_at": "2026-11-07T06:00:35.622Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01263808" } ] }